chidamide + golidocitinib

This is a combination therapy consisting of **chidamide**, a benzamide class histone deacetylase (HDAC) inhibitor, and **golidocitinib**, a selective Janus kinase 1 (JAK1) inhibitor. Chidamide modulates gene expression by inhibiting HDACs, leading to increased acetylation of histones and non-histone proteins and the subsequent induction of cell cycle arrest and apoptosis in cancer cells. Golidocitinib selectively inhibits JAK1, effectively blocking signal transduction of cytokines involved in cancer cell proliferation and survival. This combination is under investigation primarily for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), with the expectation that dual targeting of epigenetic regulation and JAK/STAT signaling may have synergistic antitumor activity[1][7].

Other names

chidamide + golidocitinib